- MolDX to hold a Contractor Advisory Committee (CAC) meeting on September 4, 2025, to discuss Medicare coverage for Lucid Diagnostics' EsoGuard® DNA Test.
- Nearly 40,000 patients have been referred for the EsoGuard test, underlining its clinical utility.
- A positive Medicare coverage decision could significantly impact Lucid Diagnostics' market potential and revenue.
Lucid Diagnostics (LUCD, Financial) has announced an upcoming MolDX Contractor Advisory Committee (CAC) meeting scheduled for September 4, 2025. The virtual session will bring together medical experts to reassess Local Coverage Determination (LCD) L39256, following Lucid Diagnostics' November 2024 request to secure Medicare coverage for its EsoGuard® Esophageal DNA Test.
The EsoGuard test has seen nearly 40,000 patient referrals, with its clinical utility supported by professional society guidelines and peer-reviewed publications. This CAC meeting marks an essential phase in the approval process, as Medicare coverage typically influences the commercial viability and accessibility of such diagnostic tests.
Lucid Diagnostics' CEO, Lishan Aklog, has expressed optimism about the meeting, citing a robust clinical evidence package and highlighting the company's strengthened balance sheet as a foundation for navigating the final stages of the Medicare coverage process. This meeting could pave the way for broader market access if a positive determination influences private payer policies.
The public can attend the CAC meeting via Microsoft Teams Webinar, but they are required to register by September 3, 2025. While public participation is limited to listening, the discussions between CAC panelists and Contractor Medical Directors will provide important clinical context and insights into the test's potential approval.
